Triheptanoin, sold under the brand name Dojolvi, is a medication for the treatment of children and adults with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

[2][3][4] The most common adverse reactions include abdominal pain, diarrhea, vomiting, and nausea.

Since triheptanoin is composed of odd-carbon fatty acids, it can produce ketone bodies with five carbon atoms, as opposed to even-carbon fatty acids which are metabolized to ketone bodies with four carbon atoms.

[4] The benefit of triheptanoin was evaluated in Trial 3 which enrolled children and adults with LC-FAOD.

[4] The benefit of triheptanoin in comparison to trioctanoin was assessed by measuring the changes in heart and muscle function.